Clinical Trials Group

ctgcro.com

CTG (Clinical Trials Group) is a private contract research organization (CRO) experienced and specialized in conducting all phases (I-IV) clinical trials in various therapeutic areas. For over 10 years, many sponsors have been benefiting from CTG's global and local scientific, regulatory and information management expertise achieving timely and high-quality clinical trials data. With an experienced and reliable team on board, CTG is a confirmed trusted partner in clinical research which is enforced by high working standards of Quality Control (QC) and Quality Assurance (QA).

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

EUROPEAN MEDICINES AGENCY ACCEPTS NOVALIQ’S MARKETING AUTHORIZATION APPLICATION FOR CYCLASOL® 0.1% FOR THE TREATMENT OF DRY EYE DISEASE

businesswire | August 25, 2023

news image

Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for CyclASol (ciclosporin ophthalmic solution) for regulatory review. CyclASol is an investigational new drug treatment for dry eye disease in patients not responding to tear substitutes. The Committee for Medicinal Products for Human Use (CHMP) of the EMA will start its review of th...

Read More

Business Insights

LOVE PHARMAS INVESTMENT IN US BIOTECH OFFERS STRATEGIC INDUSTRY ADVANTAGES AND ENHANCED SHAREHOLDER VALUE

LOVE Pharma | September 09, 2022

news image

Love Pharma Inc. an international mental health and sexual wellness company, remains extremely active in shaping itself into a real competitor in the biotech/pharmaceutical space. The company’s growth and development plan took a major leap forward this week with the announcement that Love Pharma is establishing a “strategic alliance” with Starton Therapeutics a leading clinical-stage biotechnology company in the United States. It’s a relationship that...

Read More

Pharma Tech

IKTOS ANNOUNCES DEPLOYMENT OF THEIR AI FOR DRUG DESIGN SOFTWARE MAKYA™ BY CHIESI GROUP

Iktos and Chiesi Group | December 03, 2021

news image

ktos, a company specialized in Artificial Intelligence for new drug design today announced collaboration agreement in AI for new drug design with Chiesi Group, the international research-focused pharmaceutical and healthcare. Under the agreement, Iktos’s de novo generative design software Makya™ will be used by Chiesi scientists to facilitate rapid and cost-effective design of novel compounds and accelerate hit-to-lead/lead optimisation for undisclosed Chiesi’s drug discovery p...

Read More

Business Insights

BC PLATFORMS PARTNERS WITH EU FUNDED, AI-DRIVEN, CANCER DATA INITIATIVE

BC Platforms | November 25, 2022

news image

BC Platforms a global leader in healthcare data management and analytics announced that it has been chosen as key partner in a European Commission project. Under the EC's Horizon Europe program*, Helsinki University Hospital has been awarded a contract to lead a EURO 7 million consortium project termed ONCOVALUE. BCP will work closely with HUS as a key delivery partner in this major EC project. ONCOVALUE is an Artificial Intelligence-based framework which assesses, in real-tim...

Read More
news image

Pharmacy Market

EUROPEAN MEDICINES AGENCY ACCEPTS NOVALIQ’S MARKETING AUTHORIZATION APPLICATION FOR CYCLASOL® 0.1% FOR THE TREATMENT OF DRY EYE DISEASE

businesswire | August 25, 2023

Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for CyclASol (ciclosporin ophthalmic solution) for regulatory review. CyclASol is an investigational new drug treatment for dry eye disease in patients not responding to tear substitutes. The Committee for Medicinal Products for Human Use (CHMP) of the EMA will start its review of th...

Read More
news image

Business Insights

LOVE PHARMAS INVESTMENT IN US BIOTECH OFFERS STRATEGIC INDUSTRY ADVANTAGES AND ENHANCED SHAREHOLDER VALUE

LOVE Pharma | September 09, 2022

Love Pharma Inc. an international mental health and sexual wellness company, remains extremely active in shaping itself into a real competitor in the biotech/pharmaceutical space. The company’s growth and development plan took a major leap forward this week with the announcement that Love Pharma is establishing a “strategic alliance” with Starton Therapeutics a leading clinical-stage biotechnology company in the United States. It’s a relationship that...

Read More
news image

Pharma Tech

IKTOS ANNOUNCES DEPLOYMENT OF THEIR AI FOR DRUG DESIGN SOFTWARE MAKYA™ BY CHIESI GROUP

Iktos and Chiesi Group | December 03, 2021

ktos, a company specialized in Artificial Intelligence for new drug design today announced collaboration agreement in AI for new drug design with Chiesi Group, the international research-focused pharmaceutical and healthcare. Under the agreement, Iktos’s de novo generative design software Makya™ will be used by Chiesi scientists to facilitate rapid and cost-effective design of novel compounds and accelerate hit-to-lead/lead optimisation for undisclosed Chiesi’s drug discovery p...

Read More
news image

Business Insights

BC PLATFORMS PARTNERS WITH EU FUNDED, AI-DRIVEN, CANCER DATA INITIATIVE

BC Platforms | November 25, 2022

BC Platforms a global leader in healthcare data management and analytics announced that it has been chosen as key partner in a European Commission project. Under the EC's Horizon Europe program*, Helsinki University Hospital has been awarded a contract to lead a EURO 7 million consortium project termed ONCOVALUE. BCP will work closely with HUS as a key delivery partner in this major EC project. ONCOVALUE is an Artificial Intelligence-based framework which assesses, in real-tim...

Read More